Qilu Pharmaceutical Co., Ltd.

🇨🇳China

Country: 🇨🇳China

Ownership: Private, Subsidiary

Established: 1992-08-21

Employees: 10K

Market Cap: -

Website: http://www.qilu-pharma.com

Clinical Trials

Study of VB4-845 Injection for Treating Patients With Non-muscle Invasive Bladder Cancer

Phase 3

Conditions: Non-Muscle Invasive Bladder Cancer

Interventions: Drug: VB4-845 Injection

First Posted Date: 2021-04-26

Last Posted Date: 2021-04-26

Lead Sponsor: Qilu Pharmaceutical Co., Ltd.

Target Recruit Count: 53

Registration Number: NCT04859751

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China

A Phase 1 Study to Assess the Immunogenicity of QL0605 Compared to US Neulasta in Healthy Subjects

Phase 1

Conditions: Healthy

Interventions: Drug: US Neulasta
Drug: QL0605

First Posted Date: 2020-12-03

Last Posted Date: 2020-12-03

Lead Sponsor: Qilu Pharmaceutical Co., Ltd.

Target Recruit Count: 300

Registration Number: NCT04651036

Locations: 🇩🇪
Parexel International GmbH Early Phase Clinical Unit Berlin, Berlin, Germany
🇬🇧
Parexel Early Phase Clinical Unit, London, United Kingdom

A Study Evaluates the Safety and Efficacy of WX-0593 in ALK -Positive, or ROS1-positive Non-small Cell Lung Cancer

Phase 2

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: WX-0593 Tablets

First Posted Date: 2020-11-24

Last Posted Date: 2020-11-24

Lead Sponsor: Qilu Pharmaceutical Co., Ltd.

Target Recruit Count: 176

Registration Number: NCT04641754

Locations: 🇨🇳
Thoracic Oncology I Department, Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳
The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
🇨🇳
Oncology Department, Anhui Cancer Hospital, Hefei, Anhui, China

and more 38 locations

Study Comparing WX-0593 to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients

Phase 3

Active, not recruiting

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: WX-0593 Tablets
Drug: crizotinib

First Posted Date: 2020-11-17

Last Posted Date: 2023-11-24

Lead Sponsor: Qilu Pharmaceutical Co., Ltd.

Target Recruit Count: 292

Registration Number: NCT04632758

Locations: 🇨🇳
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China

Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive and Estrogen Receptor/Progesterone Receptor Negative Breast Cancer to Evaluate the Efficiency and Safety of Treatment With Trastuzumab Plus (+) QL1209/Pertuzumab + Docetaxel.

Phase 3

Completed

Conditions: Breast Cancer

Interventions: Drug: Trastuzumab
Drug: QL1209
Drug: Pertuzumab
Drug: Docetaxel
Procedure: surgery

First Posted Date: 2020-11-16

Last Posted Date: 2024-04-19

Lead Sponsor: Qilu Pharmaceutical Co., Ltd.

Target Recruit Count: 517

Registration Number: NCT04629846

Locations: 🇨🇳
Fudan University Cancer Hospital, Shanghai, Shanghai, China
🇨🇳
Tianjin Medical University Cancer Institution & Hospital, Tianjin, Tianjin, China

To Evaluate the Efficacy and Safety of QL1206 and Xgeva in Patients With Bone Metastases From Solid Tumors

Phase 3

Conditions: Bone Metastases

Interventions: Drug: QL1206
Drug: Xgeva

First Posted Date: 2020-09-16

Last Posted Date: 2020-09-22

Lead Sponsor: Qilu Pharmaceutical Co., Ltd.

Target Recruit Count: 700

Registration Number: NCT04550949

Locations: 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳
Sun Yat-sen University Cancer Hospital, Guangzhou, Guangdong, China

A Study of QL1604 Plus Nab-paclitaxel Versus Paclitaxel in Subjects With Advanced Gastric Cancer.

Phase 2

Conditions: Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Interventions: Drug: QL1604
Drug: Paclitaxel
Drug: Nab-paclitaxel

First Posted Date: 2020-06-17

Last Posted Date: 2020-06-17

Lead Sponsor: Qilu Pharmaceutical Co., Ltd.

Target Recruit Count: 492

Registration Number: NCT04435652

Locations: 🇨🇳
Fudan University Cancer Hospital, Shanghai, Shanghai, China

QL1604 Monotherapy for dMMR or MSI-H Advanced Solid Tumors

Phase 2

Recruiting

Conditions: Advanced Malignant Tumor

Interventions: Drug: QL1604

First Posted Date: 2020-03-30

Last Posted Date: 2022-12-07

Lead Sponsor: Qilu Pharmaceutical Co., Ltd.

Target Recruit Count: 86

Registration Number: NCT04326829

Locations: 🇨🇳
West China Hospital, Sichuan University, Chengdu, Sichuan, China
🇨🇳
Fudan University Cancer Hospital, Shanghai, Shanghai, China

A Study of QL1706 in Subjects With Advanced Malignant Tumor

Phase 1

Active, not recruiting

Conditions: Advanced Malignant Tumor

Interventions: Biological: QL1706

First Posted Date: 2020-03-05

Last Posted Date: 2023-04-10

Lead Sponsor: Qilu Pharmaceutical Co., Ltd.

Target Recruit Count: 99

Registration Number: NCT04296994

Locations: 🇨🇳
Sun Yat-sen Univeisity Cancer Center, Guangzhou, Guangdong, China

Comparing the Pharmacokinetic and Safety of QL1203 and Vectibix® in Healthy Males.

Phase 1

Conditions: Healthy Males

Interventions: Drug: QL1203
Drug: Vectibix®

First Posted Date: 2020-01-21

Last Posted Date: 2020-05-19

Lead Sponsor: Qilu Pharmaceutical Co., Ltd.

Target Recruit Count: 94

Registration Number: NCT04234594

Locations: 🇨🇳
Guizhou Cancer Hospital, Guiyang, Guizhou, China
🇨🇳
First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy